We have investigated the metabolism and disposition, in rabbits, of menogaril (7-OMEN), a new anthracycline antibiotic recently introduced into clinical trials. 7-OMEN was administered by rapid i.v. injection at a dosage of 2.5 mg/kg. 7-OMEN and metabolites were assayed by high performance liquid chromatography. Plasma concentrations of 7-OMEN declined in biexponential fashion with a terminal half-life of 2.7 h. The area under the plasma concentration versus time curve was 1.3 µm × h. The systemic clearance of 7-OMEN was 57.6 ml/min/kg. No metabolite of 7-OMEN was detected in plasma. At 8 h after treatment, the cumulative urinary and biliary excretions of 7-OMEN equivalents amounted to 1.3 and 3.4% of the total administered dose, respectively. 7-OMEN was the predominant fluorescent compound in urine, but four metabolites were also seen. In bile, 7-OMEN represented only 9.6% of the cumulative excretion and six metabolites were observed. Among the organs, lungs contained the highest concentrations of parent drug. Substantial concentrations of metabolites were observed in the kidneys, liver, duodenum, and small intestine. Three of the observed metabolites of 7-OMEN have been tentatively identified as N-demethylmenogaril, 7-deoxynogarol, and N-demethyl-7-deoxynogarol.
↵1 This work was supported by a grant from the Fondation Rose et Jean Hoguet (Brussels, Belgium), by a grant from the Scientific Committee of NATO (Brussels, Belgium), and by Grant 1P50 CA 32107 from the National Cancer Institute, Department of Health and Human Services, Bethesda, MD.
↵3 To whom requests for reprints should be addressed, at University of Maryland Cancer Center, 655 West Baltimore St., Baltimore, MD 21201.
- Received July 3, 1984.
- Revision received June 19, 1985.
- Accepted July 18, 1985.
- ©1985 American Association for Cancer Research.